Cannabinoids in glioblastoma therapy: New applications for old drugs

Frontiers in Molecular Neuroscience

Volumn 11, Issue , 2018, Pages

  Dumitru, Claudia A ^a   Sandalcioglu, I Erol ^a   Karsak, Meliha ^b  

^a NORDSTADT HOSPITAL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cannabidiol; Cannabinoid receptors; Cannabinoids; Glioblastoma; Molecular mechanisms; Novel therapeutic strategies; THC

Indexed keywords

CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FOCAL ADHESION KINASE; HEAT SHOCK PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; TEMOZOLOMIDE;

ADJUVANT CHEMOTHERAPY; ANGIOGENESIS; AUTOLYSOSOME; AUTOPHAGOSOME; CANNABIS SATIVA; CELL CYCLE PROGRESSION; CELL DEATH; CHEMORADIOTHERAPY; CYTOTOXICITY; DNA MICROARRAY; DOWN REGULATION; GLIOBLASTOMA; GLIOMA STEM CELL; HUMAN; MITOCHONDRIAL MEMBRANE; NONHUMAN; PROTEIN EXPRESSION; SHORT SURVEY; TUMOR GROWTH; TUMOR INVASION; UPREGULATION;

EID: 85048994110     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2018.00159     Document Type: Short Survey

References (54)

1. Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., et al. (2009). Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin. Investig. Drugs 18, 1061–1083. doi: 10.1517/13543780903052764
2. Aguado, T., Carracedo, A., Julien, B., Velasco, G., Milman, G., Mechoulam, R., et al. (2007). Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J. Biol. Chem. 282, 6854–6862. doi: 10.1074/jbc. M608900200
3. Blázquez, C., Casanova, M. L., Planas, A., Gómez Del Pulgar, T., Villanueva, C., Fernández-Aceüero, M. J., et al. (2003). Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 17, 529–531. doi: 10.1096/fj.02-0795fje
4. Blázquez, C., Carracedo, A., Salazar, M., Lorente, M., Egia, A., González-Feria, L., et al. (2008a). Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity? Neuropharmacology 54, 235–243. doi: 10.1016/j.neuropharm.2007. 06.021
5. Blázquez, C., Salazar, M., Carracedo, A., Lorente, M., Egia, A., González-Feria, L., et al. (2008b). Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res. 68, 1945–1952. doi: 10.1158/0008-5472.CAN-07-5176
6. Blázquez, C., González-Feria, L., Alvarez, L., Haro, A., Casanova, M. L., and Guzmán, M. (2004). Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 64, 5617–5623. doi: 10.1158/0008-5472. can-03-3927
7. Brown, K. J., Laun, A. S., and Song, Z. H. (2017). Cannabidiol, a novel inverse agonist for GPR12. Biochem. Biophys. Res. Commun. 493, 451–454. doi: 10.1016/j.bbrc.2017.09.001
8. Carracedo, A., Lorente, M., Egia, A., Blázquez, C., García, S., Giroux, V., et al. (2006). The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9, 301–312. doi: 10.1016/j.ccr.2006.03.005
9. Ciaglia, E., Torelli, G., Pisanti, S., Picardi, P., D’Alessandro, A., Laezza, C., et al. (2015). Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients’ cells. Oncotarget 6, 15464–15481. doi: 10.18632/oncotarget.3895
10. De Jesús, M. L., Hostalot, C., Garibi, J. M., Sallés, J., Meana, J. J., and Callado, L. F. (2010). Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. Neurochem. Int. 56, 829–833. doi: 10.1016/j.neuint. 2010.03.007
11. Ellert-Miklaszewska, A., Ciechomska, I., and Kaminska, B. (2013). Cannabinoid signaling in glioma cells. Adv. Exp. Med. Biol. 986, 209–220. doi: 10.1007/978-94-007-4719-7_11
12. 1A receptors. Neuropharmacology 75, 155–163. doi: 10.1016/j.neuropharm.2013.07.024
13. Galanti, G., Fisher, T., Kventsel, I., Shoham, J., Gallily, R., Mechoulam, R., et al. (2008). Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol. 47, 1062–1070. doi: 10.1080/02841860701678787
14. Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J. Z., Xie, X. Q., et al. (2008). Beta-caryophyllene is a dietary cannabinoid. Proc. Natl. Acad. Sci. U S A 105, 9099–9104. doi: 10.1073/pnas.0803601105
15. Gómez Del Pulgar, T., De Ceballos, M. L., Guzmán, M., and Velasco, G. (2002). Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 277, 36527–36533. doi: 10.1074/jbc.M205797200
16. 9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br. J. Cancer 95, 197–203. doi: 10.1038/sj. bjc.6603236
17. Hassan, S., Eldeeb, K., Millns, P. J., Bennett, A. J., Alexander, S. P., and Kendall, D. A. (2014). Cannabidiol enhances microglial phagocytosis via transient receptor potential (TRP) channel activation. Br. J. Pharmacol. 171, 2426–2439. doi: 10.1111/bph.12615
18. Hernández-Tiedra, S., Fabriàs, G., Dávila, D., Salanueva, I. J., Casas, J., Montes, L. R., et al. (2016). Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization. Autophagy 12, 2213–2229. doi: 10.1080/15548627.2016.1213927
19. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161–202. doi: 10.1124/pr. 54.2.161
20. Kaplan, J. S., Stella, N., Catterall, W. A., and Westenbroek, R. E. (2017). Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc. Natl. Acad. Sci. U S A 114, 11229–11234. doi: 10.1073/pnas. 1711351114
21. Ladin, D. A., Soliman, E., Griffin, L., and Van Dross, R. (2016). Preclinical and clinical assessment of cannabinoids as anti-cancer agents. Front. Pharmacol. 7:361. doi: 10.3389/fphar.2016.00361
22. Laun, A. S., and Song, Z. H. (2017). GPR3 and GPR6, novel molecular targets for cannabidiol. Biochem. Biophys. Res. Commun. 490, 17–21. doi: 10.1016/j.bbrc. 2017.05.165
23. Liebelt, B. D., Shingu, T., Zhou, X., Ren, J., Shin, S. A., and Hu, J. (2016). Glioma stem cells: signaling, microenvironment and therapy. Stem Cells Int. 2016:7849890. doi: 10.1155/2016/7849890
24. Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., et al. (2016). The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131, 803–820. doi: 10.1007/s00401-016-1545-1
25. Lu, H. C., and Mackie, K. (2016). An introduction to the endogenous cannabinoid system. Biol. Psychiatry 79, 516–525. doi: 10.1016/j.biopsych.2015.07.028
26. Manini, I., Caponnetto, F., Bartolini, A., Ius, T., Mariuzzi, L., Di Loreto, C., et al. (2018). Role of microenvironment in glioma invasion: what we learned from in vitro models. Int. J. Mol. Sci. 19:E147. doi: 10.3390/ijms19010147
27. Marcu, J. P., Christian, R. T., Lau, D., Zielinski, A. J., Horowitz, M. P., Lee, J., et al. (2010). Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol. Cancer Ther. 9, 180–189. doi: 10.1158/1535-7163.MCT-09-0407
28. Massi, P., Valenti, M., Solinas, M., and Parolaro, D. (2010). Molecular mechanisms involved in the antitumor activity of cannabinoids on gliomas: role for oxidative stress. Cancers 2, 1013–1026. doi: 10.3390/cancers2021013
29. Mechoulam, R. (1970). Marihuana chemistry. Science 168, 1159–1166. doi: 10.1126/science.168.3936.1159
30. Mechoulam, R. (2002). Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukot. Essent. Fatty Acids 66, 93–99. doi: 10.1054/plef.2001. 0340
31. Molina-Holgado, E., Vela, J. M., Arévalo-Martin, A., Almazán, G., Molina-Holgado, F., Borrell, J., et al. (2002). Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci. 22, 9742–9753. doi: 10.1523/JNEUROSCI.22-22-09742.2002
32. Nabissi, M., Morelli, M. B., Amantini, C., Liberati, S., Santoni, M., Ricci-Vitiani, L., et al. (2015). Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner. Int. J. Cancer 137, 1855–1869. doi: 10.1002/ijc. 29573
33. Nabissi, M., Morelli, M. B., Santoni, M., and Santoni, G. (2013). Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis 34, 48–57. doi: 10.1093/carcin/bgs328
34. Nomura, D. K., Long, J. Z., Niessen, S., Hoover, H. S., Ng, S. W., and Cravatt, B. F. (2010). Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140, 49–61. doi: 10.1016/j.cell.2009.11.027
35. Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., et al. (2014). The epidemiology of glioma in adults: a ‘‘state of the science’’ review. Neuro Oncol. 16, 896–913. doi: 10.1093/neuonc/nou087
36. Pertwee, R. G. (2005). ‘‘Pharmacological actions of cannabinoids,’’ in Cannabinoids. Handbook of Experimental Pharmacology, ed. R. G. Pertwee (Berlin, Heidelberg: Springer), 1–51.
37. Petersen, G., Moesgaard, B., Schmid, P. C., Schmid, H. H., Broholm, H., Kosteljanetz, M., et al. (2005). Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. J. Neurochem. 93, 299–309. doi: 10.1111/j.1471-4159.2005.03013.x
38. Rocha, F. C., Dos Santos Júnior, J. G., Stefano, S. C., and Da Silveira, D. X. (2014). Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas. J. Neurooncol. 116, 11–24. doi: 10.1007/s11060-013-1277-1
39. Russo, E. B. (2017). Cannabidiol claims and misconceptions. Trends Pharmacol. Sci. 38, 198–201. doi: 10.1016/j.tips.2016.12.004
40. Salazar, M., Carracedo, A., Salanueva, I. J., Hernández-Tiedra, S., Lorente, M., Egia, A., et al. (2009). Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J. Clin. Invest. 119, 1359–1372. doi: 10.1172/jci37948
41. Schley, M., Ständer, S., Kerner, J., Vajkoczy, P., Schüpfer, G., Dusch, M., et al. (2009). Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res. Bull. 79, 333–337. doi: 10.1016/j. brainresbull.2009.01.011
42. Schultz, S. (2018). GW pharmaceuticals plc investor presentation—february 2018. Available online at: http://ir.gwpharm.com/static-files/e7afbad8-ab2c-4c8a-8e21-b9d3a7d36c70
43. Schultz, S., and Beyer, M. (2017). GW pharmaceuticals achieves positive results in phase 2 proof of concept study in glioma. Available online at: http://ir.gwpharm.com/static-files/cde942fe-555c-4b2f-9cc9-f34d24c7ad27
44. Scott, K. A., Dalgleish, A. G., and Liu, W. M. (2014). The combination of cannabidiol and Delta9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol. Cancer Ther. 13, 2955–2967. doi: 10.1158/1535-7163.mct-14-0402
45. Scott, K. A., Dennis, J. L., Dalgleish, A. G., and Liu, W. M. (2015). Inhibiting heat shock proteins can potentiate the cytotoxic effect of cannabidiol in human glioma cells. Anticancer Res. 35, 5827–5837.
46. Sharma, C., Al Kaabi, J. M., Nurulain, S. M., Goyal, S. N., Kamal, M. A., and Ojha, S. (2016). Polypharmacological properties and therapeutic potential of beta-caryophyllene: a dietary phytocannabinoid of pharmaceutical promise. Curr. Pharm. Des. 22, 3237–3264. doi: 10.2174/1381612822666160311 115226
47. Singer, E., Judkins, J., Salomonis, N., Matlaf, L., Soteropoulos, P., Mcallister, S., et al. (2015). Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. Cell Death Dis. 6:e1601. doi: 10.1038/cddis.2014.566
48. Solinas, M., Massi, P., Cantelmo, A. R., Cattaneo, M. G., Cammarota, R., Bartolini, D., et al. (2012). Cannabidiol inhibits angiogenesis by multiple mechanisms. Br. J. Pharmacol. 167, 1218–1231. doi: 10.1111/j.1476-5381.2012. 02050.x
49. Solinas, M., Massi, P., Cinquina, V., Valenti, M., Bolognini, D., Gariboldi, M., et al. (2013). Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. PLoS One 8:e76918. doi: 10.1371/journal.pone.0076918
50. Soroceanu, L., Murase, R., Limbad, C., Singer, E., Allison, J., Adrados, I., et al. (2013). Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res. 73, 1559–1569. doi: 10.1158/0008-5472.can-12-1943
51. Stupp, R., Mason, W. P., Van Den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl. J. Med. 352, 987–996. doi: 10.1056/NEJMoa043330
52. Torres, S., Lorente, M., Rodríguez-Fornés, F., Hernández-Tiedra, S., Salazar, M., Garcia-Taboada, E., et al. (2011). A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol. Cancer Ther. 10, 90–103. doi: 10.1158/1535-7163.MCT-10-0688
53. Velasco, G., Carracedo, A., Blázquez, C., Lorente, M., Aguado, T., Haro, A., et al. (2007). Cannabinoids and gliomas. Mol. Neurobiol. 36, 60–67. doi: 10.1007/s12035-007-0002-5
54. Wu, X., Han, L., Zhang, X., Li, L., Jiang, C., Qiu, Y., et al. (2012). Alteration of endocannabinoid system in human gliomas. J. Neurochem. 120, 842–849. doi: 10.1111/j.1471-4159.2011.07625.x